FIELD: biotechnology; genetic engineering.
SUBSTANCE: present invention relates to biotechnology and genetic engineering, in particular to a tri-specific antigen-binding molecule, while the specified antigen-binding molecule is at least quadrivalent and contains an antigen-binding site with specificity against the first antigen epitope, an antigen-binding site with specificity against the second antigen epitope, and two antigen-binding sites with specificity against the third antigen epitope.
EFFECT: invention allows for the effective use of such a molecule as a drug for the therapy of tumors.
15 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| BINDING MOLECULES INDUCING CELLULAR ACTIVATION | 2019 |
|
RU2770620C1 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| INDUCIABLE BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2800034C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
